Nafithromycin: India’s First Antibiotic to Combat Resistance
Nafithromycin, India's first antibiotic targeting Antimicrobial Resistance (AMR), aims to address drug-resistant pneumonia, which causes significant global mortality. Developed over 14 years with ₹500 crore investment and BIRAC support, it is 10 times more effective than existing treatments like azithromycin. Manufactured as "Miqnaf" by Wockhardt, the drug offers a safer, three-day regimen with minimal side effects. Pending CDSCO approval, Nafithromycin underscores India's biotech innovation and public-private collaboration, paving the way for future advancements in life-saving healthcare solutions.
Related Posts
If you like this post, please share your feedback in the comments section below so that we will upload more posts like this.
Responses